Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Serono Stories

2014-04-17 08:27:47

BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Tuesday, April 29, 2014 Time: 8:30 am EDT...

2014-04-15 04:20:53

NOTTINGHAM, England, April 15, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales. The development and manufacturing services provider, which has a well-established track record for meeting objectives while tightening development timelines for its clients, has hired...

2014-04-14 12:37:11

ALBANY, New York, April 14, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019," the global market for human reproductive technologies was valued at USD 23.0 billion in 2012 and is expected to reach USD 27.1 billion...

2014-04-08 04:21:42

NOTTINGHAM, England, April 8, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress molecules. The UK-based pharmaceutical development and manufacturing services provider has invested in GMP hot melt extrusion (HME) technology along with further milling...

2014-04-07 04:21:10

ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy EMD Serono,...

2014-04-01 08:28:55

ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 10(th) edition of the EMD Serono Specialty Digest(TM) at the 26(th) Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in Tampa, FL. The Digest is an educational resource that provides market data on health plans' management of specialty pharmaceuticals in 2013 and identifies common trends occurring across plans. The Digest is...

2014-04-01 08:28:06

- Agreement aims to identify biomarkers relevant to future therapies in the area of Systemic Lupus Erythematosus and Lupus Nephritis ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN)...

2014-03-28 08:26:50

Clinical Leader Brings Strong Drug Development Background and Expertise SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to...

2014-03-13 12:22:21

DUBLIN, Mar. 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzkt7z/orphan_drugs ) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual...

2014-03-07 08:25:14

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding...